ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Twist Bioscience Corporation Investors to Inquire About Securities Class Action Investigation - TWST

NEW YORK, Dec. 12, 2022 /PRNewswire/ --  

WHY: New York, N.Y., December 12, 2022. Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Twist Bioscience Corporation (NASDAQ: TWST) resulting from allegations that Twist may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Twist securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=10241 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On November 15, 2022, market analyst Scorpion Capital published a report on Twist. The report alleged, among other things, that Twist is "[t]he latest miniaturized 'lab-on-a-chip' scam, just like Theranos, Berkeley Lights, and other failures" and "[a] ticking time bomb that we believe is resorting to a Worldcom-esque accounting fraud[.]" The report also alleged that "Twist's reported gross margins of 45% are simply implausible," and alleged that "[m]ultiple competitors internally refer to Twist's price dumping and customer subsidy scheme as a 'Ponzi'".

On this news, Twist's stock price fell $7.57 per share, or 19%, to close at $30.43 per share on November 15, 2022, on unusually heavy trading volume. The next day, Twist's stock price fell a further $2.14 per share, or 7%, to close at $28.29 per share. The day after, Twist's shares fell a further $2.89 per share, or 10%, to close at $25.40 per share.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      cases@rosenlegal.com
      www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rosen-global-investor-counsel-encourages-twist-bioscience-corporation-investors-to-inquire-about-securities-class-action-investigation--twst-301700883.html

SOURCE Rosen Law Firm, P.A.